Pharmasset announced at October 27, 2006 that a “Late Breaker” presentation describing the results of Study 303, a 48 week

follow-on study to the Korean Phase 3 drug registration trial of

Clevudine for the treatment of Hepatitis B, will be presented at the

57th Annual Meeting of the American Association for the Study of

Liver Diseases (AASLD) being held in Boston, Massachusetts

from October 27-31, 2006. The Clevudine abstract can be viewed

on the AASLD website at http://www.aasld.org.